Clal Biotechnology Revenue vs. Total Asset

CBI Stock   41.60  2.90  6.52%   
Based on the key profitability measurements obtained from Clal Biotechnology's financial statements, Clal Biotechnology Industries may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in April. Profitability indicators assess Clal Biotechnology's ability to earn profits and add value for shareholders.
For Clal Biotechnology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Clal Biotechnology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Clal Biotechnology Industries utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Clal Biotechnology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Clal Biotechnology Industries over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between Clal Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clal Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clal Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Clal Biotechnology Total Asset vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Clal Biotechnology's current stock value. Our valuation model uses many indicators to compare Clal Biotechnology value to that of its competitors to determine the firm's financial worth.
Clal Biotechnology Industries is the top company in revenue category among related companies. It is number one stock in total asset category among related companies fabricating about  5.78  of Total Asset per Revenue. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Clal Biotechnology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Clal Biotechnology's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Clal Biotechnology's earnings, one of the primary drivers of an investment's value.

Clal Revenue vs. Competition

Clal Biotechnology Industries is the top company in revenue category among related companies. Market size based on revenue of Health Care industry is currently estimated at about 34.54 Billion. Clal Biotechnology adds roughly 76.96 Million in revenue claiming only tiny portion of equities under Health Care industry.

Clal Total Asset vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Clal Biotechnology

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
76.96 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

Clal Biotechnology

Total Asset

 = 

Tangible Assets

+

Intangible Assets

 = 
444.92 M
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.

Clal Total Asset Comparison

Clal Biotechnology is currently under evaluation in total asset category among related companies.

Clal Biotechnology Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Clal Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Clal Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of Clal Biotechnology's change in net profit over the period of time. It can combine multiple indicators of Clal Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It operates as a subsidiary of Clal Industries and Investments Ltd. CLAL BIOTECHNOLOGY operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange.

Clal Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Clal Biotechnology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Clal Biotechnology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Clal Biotechnology's important profitability drivers and their relationship over time.

Use Clal Biotechnology in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Clal Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Clal Biotechnology will appreciate offsetting losses from the drop in the long position's value.

Clal Biotechnology Pair Trading

Clal Biotechnology Industries Pair Trading Analysis

The ability to find closely correlated positions to Clal Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Clal Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Clal Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Clal Biotechnology Industries to buy it.
The correlation of Clal Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Clal Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Clal Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Clal Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Clal Biotechnology position

In addition to having Clal Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Compulsion Thematic Idea Now

Compulsion
Compulsion Theme
Companies involved in research, development, and manufacturing of products with compulsion characteristics such as cigarettes, addictive drugs and alcohol. The Compulsion theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Compulsion Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Complementary Tools for Clal Stock analysis

When running Clal Biotechnology's price analysis, check to measure Clal Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clal Biotechnology is operating at the current time. Most of Clal Biotechnology's value examination focuses on studying past and present price action to predict the probability of Clal Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clal Biotechnology's price. Additionally, you may evaluate how the addition of Clal Biotechnology to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Money Managers
Screen money managers from public funds and ETFs managed around the world
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Transaction History
View history of all your transactions and understand their impact on performance
To fully project Clal Biotechnology's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Clal Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Clal Biotechnology's income statement, its balance sheet, and the statement of cash flows.
Potential Clal Biotechnology investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Clal Biotechnology investors may work on each financial statement separately, they are all related. The changes in Clal Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Clal Biotechnology's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.